%20PRIVATE%20LIMITED%20-%20133409%2028-Feb-2011_files/image002.jpg){kind=small}
MIRA
INFORM REPORT
|
Report Date : |
28.02.2011 |
IDENTIFICATION DETAILS
|
Name : |
BIOTRON HEALTHCARE ( |
|
|
|
|
Registered
Office : |
301, Coral Classic, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2010 |
|
|
|
|
Date of
Incorporation : |
10.08.1998 |
|
|
|
|
Com. Reg. No.: |
11-116175 |
|
|
|
|
CIN No.: [Company Identification
No.] |
U33100MH1998PTC116175 |
|
|
|
|
IEC No.: |
0398001022 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
MUMB08735G |
|
|
|
|
PAN No.: [Permanent Account No.] |
AABCB1398N |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business
: |
Distributor of Quality/Innovative Products,
Technology and Services. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (44) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 29400 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually Correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is an established company having satisfactory track. Trade
relations are reported as fair. Business is active. Payments are reported to
be usually correct. The company can be considered for small business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – April 1, 2010
|
Country Name |
Previous Rating (31.12.2009) |
Current Rating (01.04.2010) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
INFORMATION PARTED BY
|
Name : |
Gayathri Ranganathan |
|
|
Designation : |
Director |
|
|
Date : |
24.01.2009 |
|
LOCATIONS
|
Registered Office : |
3rd Floor, Office No. 301, Coral Classic Commercial Complex
CHS Limited, |
|
Tel. No.: |
91-22-25287626/ 25281015 |
|
Fax No.: |
91-22-25281012 |
|
E-Mail : |
sales@biotronhealthcare.com
(For Sales Inquiries) techicals@biotronhealthcare.com
(For Application Support) service@biortronhealthcare.com (For Service / customer Support) |
|
Website : |
|
|
Area : |
1635 sq. ft. [Owned] |
|
|
|
|
Regional Office : |
301, Corporate Tower, 85A, |
|
Tel. No.: |
91-11-41727975 |
|
E-Mail : |
|
|
|
|
|
Branches : |
Located At:- ·
Ahmedabad ·
·
Chennai ·
·
·
·
Kolkata ·
|
DIRECTORS
As on 30.09.2010
|
Name : |
Mrs. Gayathri Ranganathan |
|
Designation : |
Director |
|
Address : |
C-16, 3rd Floor, Jeevan Bahar, Chembur, Mumbai-400071, |
|
Date of Birth/Age : |
22.08.1960 |
|
Qualification : |
BSc. MBA |
|
Date of Appointment : |
10.08.1998 |
|
Din : |
00145546 |
|
|
|
|
Name : |
Mr. Vankatesh Voleti |
|
Designation : |
Director |
|
Address : |
C-301, 3rd Lake View, Lake View Building No. 4, Pawai Vihar
Complex, A S Road, Powai, Mumbai-400076, Maharashtra, India |
|
Date of Birth/Age : |
17.07.1967 |
|
Qualification : |
BSc. MBA |
|
Date of Appointment : |
10.08.1998 |
|
Din : |
00145589 |
|
|
|
|
Name : |
Mr. Shrikanth Mohanrao Hangal |
|
Designation : |
Director |
|
Address : |
C-3, Sector 6, Navi Mumbai, Vashi, Mumbai-40070., |
|
Date of Birth/Age : |
20.03.1969 |
|
Qualification : |
B. E., Electronics |
|
Date of Appointment : |
10.08.1998 |
|
Din : |
00145392 |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on 30.09.2010
|
Names of Shareholders |
|
No. of Shares |
|
Gayathri Ranganathan |
|
50000 |
|
Venkatesh Voleti |
|
50000 |
|
Shrikant Hanga |
|
50000 |
|
Total |
|
150000 |
As on 30.09.2010
|
Category |
Percentage |
|
Directors or relatives of Directors |
100.00 |
|
Total |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Distributor of Quality/Innovative Products,
Technology and Services. |
|
|
|
|
Products : |
Genomics and Proteomics - Microarray Setup, 2D Gel systems,
Biochips, consumables, etc. Drug Discovery and Screening - Multi-label Detection systems, Liquid
handling for screening, Screening kits etc. Molecular Biology and Diagnostics - Complete solution from Nucleic Acid
Isolation – Amplification –Detection-Reporting Liquid Handling - Low throughput to High throughput
systems, Blood Grouping Systems, Kit manufacturing set |
GENERAL INFORMATION
|
Customers : |
End Users
|
|||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
|
No. of Employees : |
30 (Approximately) |
|||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Bankers : |
·
Corporation Bank, Chembur Branch, Tolaram
Shopping Centre, Plot No. 95/C, N.G. Acharya Marg, Chembur, Mumbai-400071,
Maharashtra, India ·
ICICI Bank, ·
HDFC Bank ·
Barclays Bank |
|||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Facilities : |
From Corporation Bank - Credit Limit Rs. 4.500 Millions [Apply for Rs. 10.000 Millions]
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
K. F. Jetsey and Company Chartered Accountant |
|
Address : |
104, |
|
Tel. No.: |
91-22-25211789 |
|
Mobile No.: |
91-22-25212964/ 65 |
|
Fax No.: |
|
|
PAN No. : |
AATPJ1658C |
CAPITAL STRUCTURE
As on 30.09.2010
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
200,000 |
Equity Shares |
Rs. 10/- each |
Rs. 2.000 Million |
|
|
|
|
|
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
150,000 |
Equity Shares |
Rs. 10/- each |
Rs. 1.500 Million |
|
|
|
|
|
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
1.500 |
0.800 |
0.210 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
5.865 |
4.329 |
3.369 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
7.365 |
5.129 |
3.579 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
14.988 |
15.428 |
6.302 |
|
|
2] Unsecured Loans |
4.280 |
5.300 |
3.408 |
|
|
TOTAL BORROWING |
19.268 |
20.728 |
9.710 |
|
|
DEFERRED TAX LIABILITIES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
26.633 |
25.857 |
13.289 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
6.009 |
5.423 |
5.910 |
|
|
Capital work-in-progress |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
1.438 |
0.998 |
0.005 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
18.677
|
15.897 |
5.299 |
|
|
Sundry Debtors |
17.504
|
20.997 |
16.952 |
|
|
Cash & Bank Balances |
1.655
|
1.361 |
0.644 |
|
|
Other Current Assets |
0.000 |
0.000 |
0.000 |
|
|
Loans & Advances |
9.243
|
7.267 |
10.970 |
|
Total
Current Assets |
47.079
|
45.522 |
33.865 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
18.007
|
20.933 |
15.041 |
|
|
Other Current Liabilities |
5.600
|
1.917 |
7.985 |
|
|
Provisions |
4.286
|
3.236 |
3.465 |
|
Total
Current Liabilities |
27.893
|
26.086 |
26.491 |
|
|
Net Current Assets |
19.186
|
19.436 |
7.374 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
26.633 |
25.857 |
13.289 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
|
51.298 |
58.226 |
|
|
|
Other Income |
|
10.863 |
1.551 |
|
|
|
TOTAL (A) |
NA |
62.161 |
59.777 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Trading Goods and Expenses |
|
38.872 |
39.519 |
|
|
|
Employee Expenses |
|
5.621 |
2.916 |
|
|
|
Other Expenses |
|
7.886 |
9.624 |
|
|
|
Marketing Expenses |
|
5.208 |
3.983 |
|
|
|
TOTAL (B) |
NA |
57.587 |
56.042 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
3.536 |
4.574 |
3.735 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
0.000 |
2.008 |
1.000 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
3.536 |
2.566 |
2.735 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
0.918 |
0.869 |
0.772 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
2.618 |
1.697 |
1.963 |
|
|
|
|
|
|
|
|
|
Less |
TAX (I) |
1.082 |
0.737 |
0.914 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-I) (J) |
1.536 |
0.960 |
1.049 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
4.329 |
3.369 |
2.320 |
|
|
|
|
|
|
|
|
|
|
BALANCE CARRIED
TO THE B/S |
5.865 |
4.329 |
3.369 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
10.24 |
-- |
-- |
|
%20PRIVATE%20LIMITED%20-%20133409%2028-Feb-2011_files/image003.gif){kind=small}
%20PRIVATE%20LIMITED%20-%20133409%2028-Feb-2011_files/image004.gif){kind=small}
KEY RATIOS
|
PARTICULARS |
|
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
PAT / Total Income |
(%) |
--
|
1.54 |
1.75 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
--
|
3.31 |
3.37 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
4.93
|
3.33 |
4.94 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.36
|
0.33 |
0.55 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
6.40
|
9.13 |
10.11 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
1.69
|
1.75 |
1.28 |
LOCAL AGENCY FURTHER INFORMATION
The Register Office of the company has been shifted from 501, Rudresh
Complex,
Bankers Charges
Report as per Registry
|
Corporate
identity number of the company |
U33100MH1998PTC116175 |
|
Name of the
company |
Biotron
Healthcare ( |
|
Address of the
registered office or of the principal place of business in |
301,Coral
Classic, |
|
This form is for |
Creation of
charge |
|
Type of charge |
|
|
Particular of
charge holder |
ICICI Bank
Limited – CIN : L65190GJ1994PLC021012 Email – shanthi.venkatesan@icicibank.com
|
|
Nature of
instrument creating charge |
Working capital
facilities of Rs. 25 million in the form of CC, BG and LC. Charge to be created
on current assets |
|
Date of
instrument Creating the charge |
26.11.2010 |
|
Amount secured by
the charge |
Rs.25.000 million |
|
Brief of the
principal terms an conditions and extent and operation of the charge |
BG
Commission 1.25% p.a. LC
Commission 1.25% p.a.
CC-40% on Book Debts LC-20% BG-20%
|
|
Short particulars
of the property or asset(s) charged (including complete address and location
of the property) |
Exclusive charge
on Current Assets of the Company |
Fixed Assets:
- Furniture and Fixture
- Computer
- Mobile Phone
- Fax Machine
- EPABX System
- Motor Car
- Refrigerator
- Telephone Instruments
- Office Fans
- Air Conditioners
- Card Scan Executive
- Deep Freezer
- Office Premises
- Labeling Machine
- Microwave Oven
- Software
- Modem
- Paper Shredding machine
- Printer
- Scanner
- Cooler
AS PER WEBSITE
Profile:
Subject was established in 1998 by a group of highly
skilled, vastly experienced and motivated professionals who now form the senior
management team. The team is supported by high caliber sales professionals and
engineers and a distributor network in the major cities of
Subject is engaged in the distribution of quality/innovative
products, technology and services from world leading manufacturers chosen
carefully for their brand value and strength of the company.
The
Products :
They broadly classify the product range in four main
categories :
Genomics and Proteomics
- Microarray Setup, 2D Gel systems, Biochips, consumables, etc.
Drug Discovery and Screening
- Multi-label Detection systems, Liquid handling for screening, Screening
kits, etc.
Molecular Biology and Diagnostics
- Complete solution from Nucleic Acid Isolation – Amplification
–Detection-Reporting
Liquid Handling
- Low throughput to High throughput systems, Blood Grouping Systems, Kit
manufacturing set
The Network :
They have established a good network of the own offices at
major cities in
They believe in providing complete customer satisfaction
through the products, the knowledge, application support and experience. All
the engineers and product specialists are well trained at the principals /
manufacturing sites or at the site.
In-house Lab :
They have set up a modern fully equipped lab at the Mumbai
Head office to facilitate new product development, application support, trouble
shooting, demonstrations and training
News
LIFESCIENCE
·
PCR- System 2/System 4 (for High Throughput PCR
Introduced) with ability to run multiple programs simultaneously. Touch screen
based control unit & virtually unlimited capacity to save programs.
·
Introducing Library Quantification Kits for Next
Generation DNA Sequencing meets Next Generation qPCR : The Universal Library
Quantification Kits from Kapa Biosystems eliminate time-consuming and expensive
titrations and reduce variability in cluster density.
·
Introducing new KAPA SYBR® FAST One-Step qRT-PCR
Kits: designed to perform optimally in stringent qRT-PCR reaction conditions,
exhibiting dramatic improvements in sensitivity, specificity, reaction efficiency,
and fluorescence.
·
CIS BIO introduces GPCR Ligand Binding Assays in
Non Radioactive format.
·
Introducing OPTIX MX3, Time Domain, Optical based
Molecular Imaging System (Animals) from ART Canada.
·
12GC Automated Nucleic Acid Extraction System from
PSS Bio,
·
Introducing The next generation HTS microplate
reader PHERAstar FS incorporates all the features one would
expect from the ultimate high-end HTS microplate reader from BMG LabTech
·
The Omega Microplate Readers are the only
Lifescience microplate readers with Tandem Technology - highly sensitive
filter based detection and ultra-fast UV/Vis spectrometer based
absorbance.
·
Introducing Automated Cell Culture System, Compound
Storage and Management Systems and related systems from
MOLECULAR
DIAGNOSTICS
- Cepheid
introduces MTB/RIF Assay performed on the GeneXpert® System....a
qualitative test designed for rapid detection of Mycobacterium
tuberculosis (MTB) and rifampicin resistance, a marker for multi-drug
resistant strains.
- Introducing
HemaVision Kit designed to detect up to 28 different chromosomal
alterations, including more than 80 breakpoints or splice variants for
particular subtypes of acute and chronic leukaemia’s.
- Ipsogen
expands its IVD offer in leukaemia diagnostic with the CE marking of JAK2
MutaQuant™ and JAK2 MutaSearch™ Kits.
- Ipsogen
further expands its offer in leukaemia diagnostic, including a new NPM1
kit and 3 new BCR-ABL products.
- Introducing Seegene
South Korea Seeplex® Influenza A/B OneStep Typing, Gel
Based Multiplex kit capable of simultaneous differentiation of the
new influenza A H1N1 virus seen in the current outbreaks, seasonal
influenza A viruses and influenza B virus in a single reaction.
- New Sacace
2010 Catalog with extended range of Real Time & Gel based detection
Kit for Human Pathogens and Veterinary now available.
- New K-RAS
Strip Assay for Ultra-Sensitive detection of Codon 12/13 Mutations from
Vienna Labs.
- Olerup SSP AB
extended range of Molecular HLA typing kits available
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government official
or a family member or close business associate of a Government official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on Corporate
Governance to identify management and governance. These factors often have been
predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.45.37 |
|
|
1 |
Rs.73.24 |
|
Euro |
1 |
Rs.62.68 |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
5 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
5 |
|
--PROFITABILIRY |
1~10 |
4 |
|
--LIQUIDITY |
1~10 |
5 |
|
--LEVERAGE |
1~10 |
5 |
|
--RESERVES |
1~10 |
5 |
|
--CREDIT LINES |
1~10 |
5 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
44 |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.